Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States

Marcus Jamil  
*Henry Ford Health System, mjamil1@hfhs.org*

Sohrab Arora  
*Henry Ford Health System, sarora3@hfhs.org*

Akshay Sood  
*Henry Ford Health System, ASOOD1@hfhs.org*

Deepansh Dalela  
*Henry Ford Health System, ddalela1@hfhs.org*

Jacob Keeley  
*Henry Ford Health System, JKeeley2@hfhs.org*

See next page for additional authors

Follow this and additional works at: [https://scholarlycommons.henryford.com/merf2019hvc](https://scholarlycommons.henryford.com/merf2019hvc)

**Recommended Citation**  
Jamil, Marcus; Arora, Sohrab; Sood, Akshay; Dalela, Deepansh; Keeley, Jacob; Rakic, Nikola; Fotouhi, Audrey; Peabody, James O; Menon, Mani; and Abdollah, Firas, "Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States" (2019). *High Value Care*. 7.  
[https://scholarlycommons.henryford.com/merf2019hvc/7](https://scholarlycommons.henryford.com/merf2019hvc/7)
Authors
Marcus Jamil, Sohrab Arora, Akshay Sood, Deepansh Dalela, Jacob Keeley, Nikola Rakic, Audrey Fotouhi, James O Peabody, Mani Menon, and Firas Abdollah

This poster is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/merf2019hvc/
Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States

Sohrab Arora¹, Marcus Jamil¹, Akshay Sood¹, Deepansh Dalela¹, Jacob Keeley¹, Nikola Rakic², U Prokopiv, Audrey Fotouhi², James O. Peabody¹, Mani Menon¹, Firas Abdollah¹

¹ Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA, ² Wayne State University School of Medicine, Detroit, MI, USA
Introduction

• Metastatic prostate cancer is associated with significant morbidity and poor overall survival.

• Recent analysis of the National Cancer Database showed that local treatment in metastatic prostate cancer may be associated with better 3-year overall survival compared to no local treatment.

• Clinical trials are currently examining the role of primary radiation or radical prostatectomy (RP) in this setting.

• While the safety of RP in localized prostate cancer is proven, few studies have looked at perioperative complication rates and cost of cytoreductive RP at a national level.
Methods

• Database used: Healthcare Cost and Utilization Project National Inpatient Sample (NIS)
**Patient cohort:** A total of 91,835 records met inclusion criteria (estimated 454,860 RPs per NIS survey weights). Of these 1,173 had cytoreductive RP (Estimated 5,835 cases).

**Primary Outcome:** Inpatient complications

**Secondary outcomes:** In-hospital mortality, individual complications, length of hospital stay, and total cost.

**HCUP cost-to-charge files** were used to calculate total cost, which was inflation-adjusted to 2014 dollars

**Covariates:** Age, race, Charlson Comorbidity score, insurance status, rural/semi-urban/urban location, income, hospital location (rural/urban), hospital teaching status, geographical location, and hospital volume
Key results

• Any inpatient complications occurred in 14.9% records; This number was higher in patients undergoing cytoreductive RP [19.1% vs. 14.9% in the nonmetastatic group; p=0.008].

• On multivariable analysis, presence of metastasis was an independent predictor for any complications (Odds ratio [Confidence interval] 1.329 [1.077-1.640] p=0.008.
Results

Figure 1: Inpatient complications of 91,835 patients with prostate cancer treated with radical prostatectomy (RP) within the NIS from 2008 to 2014, stratified by the presence of metastatic disease.
Figure 2: Length of hospital stay in days in cytoreductive RP as compared to RP in non-metastatic disease patients

Figure 3: Inflation adjusted cost in USD in cytoreductive RP as compared to RP in non-metastatic disease patients

RP: Radical prostatectomy
Conclusion

- cRP is associated with higher inpatient morbidity, longer hospital stay, and higher cost compared to RP for nonmetastatic disease.
- This information may be valuable for informed decision-making in practice and before recruiting patients in clinical trials on this subject.